HEC-59 cells

ArtNr	C0026001
Hersteller	Addexbio
Menge	One Frozen vial
Kategorie	Oncology Food Safety Hormones Metabolism Diabetes Cell Lines & Cell Culture Cell Lines By Organ Uterine, Ovarian & Cervical Cancer
Typ	Tumour Cells
Dry ice	Yes
Citations	1.Hiramatsu, H. P., Kikuchi, Y., Seto, H., and Nagata, I. In vitro sensitivity of human endometrial cancer cell lines HEC-59 to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs. Anticancer Drugs, 11: 573-578, 2000. 2.Suzuki, T., Sasano, H., Sasaki, H., Fukaya, T., and Nagura, H. Quantitation of P450 aromatase immunoreactivity in human ovary HEC-59 during the menstrual cycle: relationship between the enzyme activity and immunointensity. J Histochem Cytochem, 42: 1565-1573, 1994. 3.Sasaki, H. [Aromatase activities of endometrial carcinomas HEC-59 and both basic and clinical analyses of endometrial hyperplasia as a premalignant disease]. Nihon Sanka Fujinka Gakkai Zasshi, 45: 763-775, 1993. 4.Tada, A., Sasaki, H., Nakamura, J., Yoshihama, M., and Terashima, Y. Aromatase activity and the effect of estradiol and testosterone on DNA synthesis in endometrial carcinoma cell lines HEC-59. J Steroid Biochem Mol Biol, 44: 661-666, 1993. 5.Yamamoto, T., Kitawaki, J., Urabe, M., Honjo, H., Tamura, T., Noguchi, T., Okada, H., Sasaki, H., Tada, A., Terashima, Y., and et al. Estrogen productivity of endometrium and endometrial cancer tissue; influence of aromatase on proliferation of endometrial cancer cells HEC-59. J Steroid Biochem Mol Biol, 44: 463-468, 1993. 6.Sasaki, H., Mitsunaga, S., Kitamura, T., Kishino, Y., Toyoizumi, T., Ogawa, M., Yamauchi, S., Iwata, M., Terashima, Y., and Mochizuki, S. [Radioresistant elements in adenocarcinoma of the uterus HEC-59]. Nihon Sanka Fujinka Gakkai Zasshi, 38: 1587-1594, 1986.
ECLASS 10.1	32160890
ECLASS 11.0	32160890
UNSPSC	41106509
Lieferbar
Description	Disease: Endometrial Carcinoma G2 Origin: Derived from endometrial carcinoma Species: Homo sapiens Tissue: Uterus Morphology: Epithelial Properties: Adherent Cytogenic data: Tumorigenic Patient: Female, Asian Medium: IMDM + 10% FBS Subculture: 1:2 to 1:5 using 0.25% trypsin or trypsin/EDTA, 5% CO2; 37C Freezing Medium: Complete culture medium supplemented with 5% (v/v) DMSO Biosafety Level: I Sterility: Bacteria: Negative Yeast: Negative Mycoplasma: Negative Pathogens: HIV: Negative Hepatitis B: Negative Hepatitis C: Negative Isoenzymes: G6PD(typeB), NP, LDH DNA Profile (STR): D5S818:10, 11, 12; D13S317:9, 10, 11; D7S820:10, 11, 14; D16S539:11, 12, 13; VWA:17, 20, 22; TH01:7, 9.3; Amelogenin:X; TPOX:11, 14; CSF1PO:9, 10 Mutations in HEC-59 Cells Related cells by Organ: HEC-59 cells HeLa cells SiHa cells CaSKi cells C33A cells
Storage condition	LN2
Manufacturers Category	Cell Lines

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.